1 / 15

Case Presentation

Case Presentation . 성균관대학교 의과대학 2007313075 손의영. Chief Complain. 김 O 식 , M/83 Dyspnea Onset : 2 weeks ago. Present Illness. 2011.02 TB pleurisy 로 치료 받은 후에 간헐적으로 dyspnea 호소 2000.03.09 Pneumonia w/ respiratory failure 로 입원 후 치료받고 퇴원 2009. 우울증 진단 후 1 년간 medication 복용

jill
Download Presentation

Case Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Case Presentation 성균관대학교 의과대학 2007313075 손의영

  2. Chief Complain • 김O식, M/83 • Dyspnea • Onset : 2 weeks ago

  3. Present Illness • 2011.02 TB pleurisy로 치료 받은 후에 간헐적으로 dyspnea호소 • 2000.03.09 Pneumonia w/ respiratory failure로 입원 후 치료받고 퇴원 • 2009. 우울증 진단 후 1년간 medication 복용 • 이후 1년에 약 1차례 씩 감기로 인한 dyspnea로 입원 치료 함

  4. Present Illness • 2011.04.05 cough, yellowish sputum 증가dyspnea aggravation  충주의료원 방문 Chest PA 상 Rt. Bronchopneumonia, COPD 의심되어 ICU 입원 • 2011.04.06 Foley catheter insertion • 2011.04.07 insomnia, hallucination 및 말이 많아지는 양상 보임 • 2011.04.09 스스로 line remove 하려고 하며 irritability 발생 ABGA 7.388 – 65.1 – 65.2 – 38.4 SpO2 91.7% CO2 retention aggravation 되어 보호자가 원하여 본원 내원

  5. Other History • PMHx. • HTN/DM/Tb/hepatitis/Allergy ( + / + / - / - / - ) • 약물력 • Drugs for Depression (During 1 hour) • 2011.04.05. : ciprofloxacin, Tazobactam, Erythromycin • 2011.04.10. : Tazobactam, Levofloxacin으로 항생제 변경 • 수술력 • 없음 • FHx. • 특이사항 없음 • SHx. • Smoking: ex-smoker 30PA (30yr x 1 pack)

  6. Review of system • GW / EF ( + / + ) • Weight change ( - ) • Fever / chill ( - / - ) • Headache / dizziness ( - / - ) • Rhinorrhea / cough/ sputum ( - / + / + ) : yellowish • Dyspnea (+) : ATS grade III • chest pain / palpitation ( - / - ) • Anorexia / nausea / vomiting ( - / - / - ) • abdominal pain / discomfort ( - / - ) • Constipation / diarrhea ( - / - ) • Hematemesis / melena / hematochezia( - / - / - ) • Urinary Sx( - ) • Arthralgia( - ) • Myalgia( - )

  7. Physical Exam • V/S 140/83mmHg - 108- 24- 36℃ • G/A Chronic ill-looking appearance • Mentality Alert & well orientation • HEENT not anemic conjunctivae, anictericsclerae Dehydrated tongue (-) PNS tenderness(-) PTH/PI (-/-) JVP (-) Neck VE (-) Cervical LNE (-/-) Thyroid enlagement (-) • Chest Symmetric chest expansion Iregularheart beat w/o murmur Clean breathing sound w/o wheezing

  8. Physical Exam • Abdomen Soft & flat Bowel sound – normoactive No tenderness/rebound tenderness No shifting dullness • Back No CVAT • Extremities Skin rash(-) Clubbing (-) Joint ROM limitation (-) Joint swelling & stiffness (-) Joint deformity (-)

  9. Spirometry / EKG

  10. Imaging

  11. Lab • WBC▲ 11.25 x10³/μL • Neut.▲ 92.2% (seg.) • Eo. 0.1% • RBC▼ 3.80 x10³/μL • Hb▼ 11.3 g/dL • Hct▼ 36.1% • PLT262,000/μL • Protein▼ 4.2 g/㎗ • Albumin▼ 2.7 g/㎗ • Globulin▼1.5 g/㎗ • AST35 U/l • ALT37 U/l • ALP 77 U/l • BUN 21 mg/dL • Cr 0.92 mg/dL • BUN/Cr 23.0 • CRP▲ 4.06 mg/dL • Na 140 mmol/ℓ • K▼3.4 mmol/ℓ • Cl▼ 96 mmol/ℓ

  12. Problem List / Assessment • Problem List • #1. Dyspnea • #2. Depression • #3. Mania • #4. Aggravation of Coughand Sputum • #5. CO2 retention • #6. Leukocytosis • #7. increased CRP • Assessment • #1, 4, 5, 6, 7 : R/O Acute Exacerbation of COPD • #2, 3 : Bipolar disorder

  13. AE of COPD – Etiology • Primary • Tracheobronchial infection • Air pollution • Secondary • Pneumonia • Pulmonary embolism • Pneumothorax • Rib fracture / Chest trauma • Inappropriate use of sedatives, narcotics, β-blocking agents • Right and/or Left heart failure or arrhythmias

  14. AE of COPD –

  15. Lung cancer – Px • Non-small lung cancer의 Stage에 따른 예후 • Stage IA : MSD 60개월 / 5YSR 50% • Stage IB : MSD 43개월 / 5YSR 43% • Stage IIA: MSD 34개월 / 5YSR 36% • Stage IIB: MSD 18개월 / 5YSR 25% • Stage IIIA: MSD 14개월 / 5YSR 19% • Stage IIIB: MSD 10개월 / 5YSR 7% • Stage IV : MSD 6개월 / 5YSR 2%

More Related